First Wave soars on starting patient dosing in pancreatic disorder drug trial

GridAI Technologies

09/03/2023 12:37

** Shares of drug developer First Wave BioPharma Inc  FWBI.O  rise 21% to
$4.3 premarket
    ** Co begins patient dosing in mid-stage study of a treatment for a type of
pancreatic disorder associated with cystic fibrosis 
    ** Topline results from the study expected by mid-2023 - FWBI
    ** Three clinical trial sites in the U.S. will be participating in the trial
designed to investigate the safety, tolerability and efficacy of the drug
    ** Cystic fibrosis is a genetic disorder that affects the cells that produce
mucus, sweat and digestive juices 
    ** Stock down 98% in last 12 months

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))